preprint · SSRN Electronic Journal

Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): a randomised, open-label, non-inferiority, 96-week trialevaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

Diana Anena
Ben Spittle
Moses Chitsamatanga
David Burger
George Patrick Akabwai
Alasdair Bamford
Alexandra Green
Lungile Jafta
Lisanne A. H. Bevers
Simon Walker
Elizabeth Chappell
Cecilia Kiilu
Rashidah Nazzinda
Adeodata Kekitiinwa
Mutsa Bwakura‐Dangarembizi
Stella Namukwaya
Janet Seeley
Moherndran Archary
Margaret J. Thomason
Abraham Siika
Deborah Ford
Naomi Apoto
M. A. Bush
Cissy Kityo
Henry Mugerwa
T. Arumugam
Annabelle South
Sarah Pett

2025Open accessMoi University

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.2139/ssrn.5671058

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.

In plain language

Read the original research

Discuss this research